Clinical trial
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
NCT01668719 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- September 22, 2025
- Enrollment
- 142 (actual)
- Sites
- 417
Conditions
As the registry lists them; a condition with its own page is linked.
ds stage i plasma cell myeloma, ds stage ii plasma cell myeloma, ds stage iii plasma cell myeloma